Patients with higher pretreatment levels of tumor PD-L1 expression (≥1%) had longer median PFS (mPFS) than patients with PD-L1 expression <1%/indeterminate in both the BEMPEG + NIVO arm (mPFS, PD-L1 ≥ 1%: 6.24 months [95% CI: 4.47–10.45] vs. PD-L1 < 1%/indeterminate: 2.43 months [95% CI: 2.20–4.17]) and the NIVO monotherapy arm (mPFS, PD-L1 ≥ 1%: 10.51 months [95% CI: 6.05–28.88] vs. PD-L1 < 1%/indeterminate: 2.37 months [95% CI: 2.17–4.17]) (Fig. 1b). This evidence concerns the gene CD274 and neoplasm.